|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/13/20 Adaptimmune Therapeutics PLC 8-K:5,8,9 1/13/20 13:396K Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 36K 2: EX-10.1 Material Contract HTML 83K 3: EX-10.2 Material Contract HTML 42K 4: EX-99.1 Miscellaneous Exhibit HTML 15K 9: R1 Cover HTML 49K 8: XML IDEA XML File -- Filing Summary XML 12K 10: XML XBRL Instance -- tm201697d1_8k_htm XML 15K 13: EXCEL IDEA Workbook of Financial Reports XLSX 6K 6: EX-101.LAB XBRL Labels -- adap-20200113_lab XML 97K 7: EX-101.PRE XBRL Presentations -- adap-20200113_pre XML 64K 5: EX-101.SCH XBRL Schema -- adap-20200113 XSD 13K 11: JSON XBRL Instance as JSON Data -- MetaLinks 25± 34K 12: ZIP XBRL Zipped Folder -- 0001104659-20-003256-xbrl Zip 41K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i January 13, 2020
i ADAPTIMMUNE THERAPEUTICS PLC
(Exact name of registrant as specified in its charter)
| i England and Wales | i 1-37368 | Not Applicable | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
i 60 Jubilee Avenue, i Milton Park
i Abingdon, Oxfordshire i OX14 4RX
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| i ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| i ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| i ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| i ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 13, 2020 Adaptimmune Therapeutics plc (the “Company”) announced the appointment of Elliot Norry as Senior Vice President (“SVP”) and Chief Medical Officer effective as of January 13, 2020 and additional changes to its R&D leadership.
On January 13, 2020, Dr. Norry entered into an employment agreement (the “Employment Agreement”) with the Company’s U.S. subsidiary, Adaptimmune LLC (the “Employer”). Under the terms of the Employment Agreement, effective January 13, 2020, Dr. Norry will receive an annual base salary of $390,000, which may be modified by the Employer in its sole discretion. In addition to the base salary, Dr. Norry will be eligible to receive an annual discretionary bonus following the end of each calendar year that ends during his employment period when he serves as SVP and Chief Medical Officer (“Annual Bonus”), subject to: (i) objective criteria set forth by the Board or an authorized delegate thereof on an annual basis; and (ii) the overall performance of the Company. The initial target Annual Bonus effective from January 13, 2020 will be thirty percent of Dr. Norry’s base salary. The Annual Bonus payment will be pro-rated for any partial year of service.
Dr. Norry will also be eligible to participate in the equity plans sponsored and/or maintained by the Company and its affiliates from time to time, in accordance with the terms of any such plans, at the sole and absolute discretion of the Company and the Board or the remuneration committee. On such date as the Board or the remuneration committee may determine and subject to the rules of the relevant equity plan and any applicable legal or regulatory requirements, Dr. Norry will be awarded 100,800 market value options to acquire ordinary shares in the Company and 67,800 RSU-style options to acquire ordinary shares in the Company on the condition that, at the time of the award of such stock options, Dr. Norry continues to serve as the Company’s SVP and Chief Medical Officer and remains employed by the Company and is not under notice of termination (given or received). The options will vest over a period of four years from the date of grant. The market value options will have an exercise price per ordinary share of not less than one sixth of the closing trading price of the Company’s American Depositary Shares on the last business day prior to the date of grant, translated from USD to GBP, and the RSU-style options will have an exercise price of £0.001 per ordinary share. Dr. Norry will also be entitled to additional employee benefits.
The Company may terminate Dr. Norry’s employment with or without cause and without notice, but Dr. Norry is required to provide at least 30 days’ advance written notice to the Company in order to terminate his employment. Dr. Norry will be entitled to payments under the Company’s SVP severance policy in the event of a termination by the Company without cause or a resignation by Dr. Norry for good reason without a change of control and upon a change of control. The Employment Agreement also contains non-solicitation and non-competition provisions for a six month period as well as standard confidentiality provisions.
The foregoing summary of the Employment Agreement is qualified in its entirety by reference to the complete text of the Employment Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The SVP severance policy is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 8.01 | Other Events |
On January 13, 2020 the Company issued a press release announcing the appointment of Dr. Norry and additional changes to its R&D leadership. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description of Exhibit | |
| 10.1 | Employment Agreement dated as of January 13, 2020 by and between Adaptimmune, LLC and Elliot Norry | |
| 10.2 | Senior Vice President Severance Policy dated December 4, 2019 | |
| 99.1 | Press release dated January 13, 2020 | |
| 104 | Cover Page lnteractive Data File (embedded within the Inline XBRL document). |
C:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
ADAPTIMMUNE THERAPEUTICS PLC | ||
| Date: January 13, 2020 | By: | /s/ Margaret Henry |
| Name: Margaret Henry | ||
| Title: Corporate Secretary | ||
C:
C:
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / For Period end: | 1/13/20 | 3, 4, 8-K | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/06/24 Adaptimmune Therapeutics plc 10-K 12/31/23 131:16M Toppan Merrill Bridge/FA 4/18/23 Adaptimmune Therapeutics plc S-4/A 7:5.6M Toppan Merrill/FA 4/05/23 Adaptimmune Therapeutics plc S-4 7:4.5M Toppan Merrill/FA 3/06/23 Adaptimmune Therapeutics plc 10-K 12/31/22 117:15M Toppan Merrill Bridge/FA 3/14/22 Adaptimmune Therapeutics plc 10-K 12/31/21 109:13M Toppan Merrill Bridge/FA 2/25/21 Adaptimmune Therapeutics plc 10-K 12/31/20 112:13M Toppan Merrill Bridge/FA 8/10/20 Adaptimmune Therapeutics plc S-3ASR 8/10/20 5:1.6M Toppan Merrill/FA |